Journal
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
Volume 4, Issue 3, Pages 1050-1065Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.1c00074
Keywords
multiple myeloma; drug resistance; ABC transporters; SLC transporters
Categories
Ask authors/readers for more resources
The review evaluates the resistance of multiple myeloma patients to novel therapies, particularly focusing on the mechanisms of resistance to proteasome inhibitors and immunomodulatory drugs, as well as the role of transporters in drug resistance.
Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available